RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Keytruda takes on adcetris in battle against tough hodgkin lymphoma
Disease control CompletedThis completed Phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) works better than the targeted drug brentuximab vedotin (Adcetris) for people with classical Hodgkin lymphoma that has relapsed or not responded to prior therapy. 304 participants were ran…
Matched conditions: RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New antibody shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedThis study tested a new drug called AZD7789 in 45 people with classical Hodgkin lymphoma that had returned or not responded to at least two prior treatments. The drug is a special antibody designed to help the immune system fight cancer cells. The main goals were to check safety …
Matched conditions: RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC